LYDIA MUELLER: Open Payments
NPI 1902669997 · WICHITA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,117 in 70 payments from 17 companies in 2025. Trend: 2023 $0 · 2024 $1,010 · 2025 $1,117
Food & beverage: $1,117
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 16 | $223 |
| AstraZeneca Pharmaceuticals LP | 4 | $201 |
| Lilly USA, LLC | 12 | $164 |
| Novo Nordisk Inc | 17 | $161 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $70 |
| Amgen Inc. | 3 | $48 |
| Sumitomo Pharma America, Inc. | 2 | $37 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $28 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $28 |
| Medtronic, Inc. | 1 | $24 |
Products named: BREZTRI, TRELEGY ELLIPTA, MOUNJARO, XIFAXAN, JARDIANCE, Ozempic, Wegovy, AIRSUPRA.
Industry payments across KS — which companies pay providers there.
